학술논문
The need for PCSK9 inhibitors and associated treatment costs according to the 2019 ESC dyslipidaemia guidelines vs. the risk-based allocation algorithmof the 2017 ESC consensus statement: a simulation study in a contemporary CAD cohort.
Document Type
Article
Author
Source
European Journal of Preventive Cardiology; Jan2021, Vol. 28 Issue 1, p47-56, 10p
Subject
Language
ISSN
20474873